Janko Kos Selected Research

nitroxoline

12/2020	Synthesis of Novel Nitroxoline Analogs with Potent Cathepsin B Exopeptidase Inhibitory Activity.
12/2019	Nitroxoline: repurposing its antimicrobial to antitumor application.
9/2019	Organoruthenated Nitroxoline Derivatives Impair Tumor Cell Invasion through Inhibition of Cathepsin B Activity.
1/2018	Cathepsin B inhibitors: Further exploration of the nitroxoline core.
8/2017	Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo.
8/2015	Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity.
1/2013	Development of new cathepsin B inhibitors: combining bioisosteric replacements and structure-based design to explore the structure-activity relationships of nitroxoline derivatives.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Janko Kos Research Topics

Disease

74	Neoplasms (Cancer) 04/2022 - 01/2000
24	Neoplasm Metastasis (Metastasis) 03/2022 - 11/2002
10	Alzheimer Disease (Alzheimer's Disease) 03/2019 - 08/2013
8	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2022 - 09/2012
8	Pathologic Processes 01/2022 - 04/2006
7	Glioblastoma (Glioblastoma Multiforme) 02/2022 - 05/2002
7	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2000
6	Inflammation (Inflammations) 04/2022 - 08/2006
6	Glioma (Gliomas) 02/2022 - 05/2002
5	Prostatic Neoplasms (Prostate Cancer) 05/2020 - 12/2011
4	Neuroblastoma 01/2022 - 01/2010
4	Neuroinflammatory Diseases 11/2021 - 01/2017
4	Brain Neoplasms (Brain Tumor) 10/2021 - 01/2000
4	Infections 01/2014 - 08/2009
4	Squamous Cell Carcinoma of Head and Neck 11/2013 - 06/2004
4	Carcinoma (Carcinomatosis) 08/2007 - 05/2003
3	Disease Progression 01/2022 - 08/2007
3	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 09/2012
3	Carcinogenesis 01/2013 - 05/2004
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 07/2014
2	Atherosclerosis 07/2019 - 10/2013
2	Parkinson Disease (Parkinson's Disease) 01/2018 - 07/2014
2	Fibrosarcoma 08/2017 - 08/2015
2	B-Cell Lymphoma (Lymphoma, B Cell) 02/2011 - 04/2007
2	Ovarian Neoplasms (Ovarian Cancer) 07/2010 - 05/2010
2	Astrocytoma (Pilocytic Astrocytoma) 12/2009 - 05/2002
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2006 - 05/2003
2	Lung Neoplasms (Lung Cancer) 05/2005 - 05/2003
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 01/2022

Drug/Important Bio-Agent (IBA)

44	CathepsinsIBA 04/2022 - 01/2002
29	Cysteine (L-Cysteine)FDA Link 04/2022 - 01/2002
24	Peptide Hydrolases (Proteases)FDA Link 04/2022 - 05/2002
20	Cathepsin BIBA 01/2022 - 01/2000
18	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
14	Cysteine Proteases (Cysteine Protease)IBA 07/2019 - 01/2000
9	CystatinsIBA 10/2021 - 05/2002
8	Protease Inhibitors (Protease Inhibitor)IBA 01/2022 - 05/2002
8	Cystatin CIBA 03/2019 - 06/2004
8	Cystatin AIBA 11/2013 - 01/2000
7	CarboxypeptidasesIBA 02/2022 - 08/2006
7	Phosphopyruvate Hydratase (Enolase)IBA 02/2022 - 01/2010
7	nitroxolineIBA 12/2020 - 01/2013
7	Biomarkers (Surrogate Marker)IBA 07/2019 - 01/2002
7	Pharmaceutical PreparationsIBA 11/2018 - 08/2004
6	EnzymesIBA 01/2022 - 01/2002
6	AntibodiesIBA 03/2020 - 01/2000
6	ButyrylcholinesteraseIBA 03/2019 - 10/2014
5	Messenger RNA (mRNA)IBA 10/2021 - 01/2000
5	LigandsIBA 09/2019 - 01/2015
5	Monoclonal AntibodiesIBA 08/2008 - 11/2002
4	Cathepsin LIBA 10/2021 - 01/2002
4	cathepsin SIBA 07/2019 - 01/2009
3	IntegrinsIBA 03/2022 - 01/2013
3	Monoamine Oxidase (MAO)IBA 01/2022 - 01/2017
3	AntigensIBA 01/2021 - 01/2000
3	Anti-Infective Agents (Microbicides)IBA 12/2020 - 08/2017
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2020 - 12/2018
3	Cholinergic Agents (Cholinergics)IBA 11/2018 - 12/2016
3	Amyloid (Amyloid Fibrils)IBA 01/2018 - 08/2013
3	Profilins (Profilin)IBA 04/2015 - 01/2013
3	Extracellular Matrix ProteinsIBA 07/2014 - 11/2002
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2014 - 08/2009
3	Cathepsin HIBA 01/2013 - 01/2009
3	Cystatin BIBA 05/2011 - 01/2002
3	Cysteine Proteinase InhibitorsIBA 04/2007 - 06/2004
2	Hormones (Hormone)IBA 03/2022 - 12/2018
2	Biological ProductsIBA 01/2021 - 01/2019
2	InterferonsIBA 03/2020 - 01/2020
2	Chimeric Antigen ReceptorsIBA 03/2020 - 01/2020
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2018 - 12/2015
2	Cathepsin KIBA 10/2018 - 10/2018
2	Oxidopamine (6 Hydroxydopamine)IBA 01/2018 - 07/2014
2	CollagenIBA 01/2018 - 08/2015
2	CytokinesIBA 12/2015 - 12/2011
2	ChemokinesIBA 12/2015 - 04/2015
2	EndopeptidasesIBA 08/2015 - 05/2002
2	RNA (Ribonucleic Acid)IBA 04/2015 - 05/2002
2	SolutionsIBA 05/2012 - 12/2005
2	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 10/2009 - 01/2002
2	Keratins (Keratin)IBA 08/2008 - 09/2007
2	ImmunosorbentsIBA 08/2007 - 01/2002
2	Polyglactin 910IBA 12/2004 - 08/2004
1	Integrin alphaVbeta3IBA 03/2022
1	Endocrine DisruptorsIBA 03/2022
1	DioxinsIBA 01/2022
1	TriazolesIBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	Protein AggregatesIBA 01/2022
1	Immune Checkpoint ProteinsIBA 01/2022
1	Epithelial Cell Adhesion MoleculeIBA 01/2021
1	human ERBB2 proteinIBA 01/2021
1	Carrier Proteins (Binding Protein)IBA 01/2021
1	IndazolesIBA 01/2021
1	Antiparkinson Agents (Antiparkinsonian Agents)IBA 01/2021
1	CLIK 148IBA 09/2020
1	Granzymes (Granzyme)IBA 02/2020
1	PerforinIBA 02/2020

Therapy/Procedure

21	Therapeutics 04/2022 - 08/2004
4	Immunotherapy 03/2020 - 01/2018
2	Drug Therapy (Chemotherapy) 12/2018 - 04/2015